T. Rowe Price Associates’s Veracyte VCYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.93M | Buy |
90,948
+16,270
| +22% | +$602K | ﹤0.01% | 1662 |
|
|
2025
Q4 | $3.14M | Buy |
74,678
+5,881
| +9% | +$237K | ﹤0.01% | 1565 |
|
|
2025
Q3 | $2.36M | Buy |
68,797
+4,063
| +6% | +$117K | ﹤0.01% | 1659 |
|
|
2025
Q2 | $1.75M | Buy |
64,734
+6,931
| +12% | +$201K | ﹤0.01% | 1699 |
|
|
2025
Q1 | $1.71M | Buy |
57,803
+9,389
| +19% | +$358K | ﹤0.01% | 1681 |
|
|
2024
Q4 | $1.92M | Buy |
48,414
+1,816
| +4% | +$68.8K | ﹤0.01% | 1669 |
|
|
2024
Q3 | $1.59M | Buy |
46,598
+1,894
| +4% | +$53.3K | ﹤0.01% | 1748 |
|
|
2024
Q2 | $969K | Buy |
44,704
+3,663
| +9% | +$77K | ﹤0.01% | 1909 |
|
|
2024
Q1 | $910K | Buy |
41,041
+4,256
| +12% | +$104K | ﹤0.01% | 1950 |
|
|
2023
Q4 | $1.01M | Buy |
36,785
+6,499
| +21% | +$157K | ﹤0.01% | 1864 |
|
|
2023
Q3 | $677K | Sell |
30,286
-3,463
| -10% | -$89.1K | ﹤0.01% | 1972 |
|
|
2023
Q2 | $860K | Buy |
33,749
+2,099
| +7% | +$50.9K | ﹤0.01% | 1878 |
|
|
2023
Q1 | $706K | Buy |
31,650
+1,242
| +4% | +$30K | ﹤0.01% | 1955 |
|
|
2022
Q4 | $722K | Sell |
30,408
-926
| -3% | -$21.5K | ﹤0.01% | 1958 |
|
|
2022
Q3 | $521K | Buy |
31,334
+298
| +1% | +$6.71K | ﹤0.01% | 2099 |
|
|
2022
Q2 | $618K | Buy |
31,036
+2,537
| +9% | +$51.3K | ﹤0.01% | 2134 |
|
|
2022
Q1 | $786K | Buy |
28,499
+4,998
| +21% | +$143K | ﹤0.01% | 2121 |
|
|
2021
Q4 | $968K | Sell |
23,501
-8,364
| -26% | -$370K | ﹤0.01% | 2057 |
|
|
2021
Q3 | $1.48M | Buy |
31,865
+1,261
| +4% | +$55K | ﹤0.01% | 1858 |
|
|
2021
Q2 | $1.22M | Buy |
30,604
+2,653
| +9% | +$113K | ﹤0.01% | 1987 |
|
|
2021
Q1 | $1.5M | Buy |
27,951
+12,887
| +86% | +$742K | ﹤0.01% | 1851 |
|
|
2020
Q4 | $737K | Sell |
15,064
-10,043
| -40% | -$465K | ﹤0.01% | 2078 |
|
|
2020
Q3 | $816K | Buy |
25,107
+14,698
| +141% | +$467K | ﹤0.01% | 1899 |
|
|
2020
Q2 | $270K | Sell |
10,409
-11,630
| -53% | -$290K | ﹤0.01% | 2269 |
|
|
2020
Q1 | $536K | Buy |
22,039
+7,074
| +47% | +$178K | ﹤0.01% | 1957 |
|
|
2019
Q4 | $418K | Sell |
14,965
-72,072
| -83% | -$1.87M | ﹤0.01% | 2218 |
|
|
2019
Q3 | $2.09M | Buy |
+87,037
| New | +$2.32M | ﹤0.01% | 1565 |
|
|
2017
Q3 | – | Sell |
-21,492
| Closed | -$179K | – | 2588 |
|
|
2017
Q2 | $179K | Sell |
21,492
-4,349
| -17% | -$35.5K | ﹤0.01% | 2402 |
|
|
2017
Q1 | $237K | Buy |
+25,841
| New | +$211K | ﹤0.01% | 2341 |
|
|
2014
Q4 | – | Sell |
-43,057
| Closed | -$420K | – | 2565 |
|
|
2014
Q3 | $420K | Buy |
+43,057
| New | +$565K | ﹤0.01% | 2012 |
|
Other funds holding VCYT
VPM
VCM
AIM
T. Rowe Price Associates's VCYT Position: Q1 2026 in Review
T. Rowe Price Associates increased its Veracyte (VCYT) stake by 22% in Q1 2026, buying an estimated $602K and bringing the position to 90,948 shares worth $2.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1662.
T. Rowe Price Associates first reported a position in VCYT in Q3 2014 and has held it in 30 quarters since. The position peaked at $3.14M in Q4 2025. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.
- T. Rowe Price Associates held 90,948 shares of Veracyte worth $2.93M as of Q1 2026.
- T. Rowe Price Associates bought 16,270 Veracyte shares in Q1 2026, an estimated $602K.
- Veracyte made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1662 holding.
- T. Rowe Price Associates first reported a position in Veracyte in Q3 2014 and has held it in 30 quarters since.
- T. Rowe Price Associates's Veracyte position peaked at $3.14M in Q4 2025.
- 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.